Although marijuana still is classified under the Controlled Substances Act (CSA) as a Schedule I substance, the Food and Drug Administration (FDA) approved Epidiolex for sale in the U.S. This first prescription drug derived from the marijuana plant is designed to treat seizures for Dravet Syndrome and Lennox-Gastaut Syndrome. GW Pharmaceuticals expects to make the drug available in the States after the Drug Enforcement Administration (DEA) assigns it a new controlled-substance classification. Employers wondering how to treat drug testing for those employees prescribed Epidiolex will need to wait to see if guidelines are provided.
Read more
